Cambridge id 5427953 | 76087-24-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Cambridge id 5427953
• 英文别名: 1-methyl-4-(3-phenylpropyl)piperazine
• CAS: 76087-24-6
• 化学式: C₁₄H₂₂N₂
• 分子量: 218.342
• InChiKey: VDMPTTZAUYEXDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N'-methyl-N-(3-phenylprop-2-ynyl)piperazine 在 1.3 wt% Ru(0) nanoparticles and covalently functionalized 4.9 wt% Cu(I) N-heterocyclic carbene complex jointly assembled on silica 作用下， 100.0 ℃ 、500.01 kPa 条件下， 以50 %的产率得到Cambridge id 5427953
  参考文献：
  名称：

  使用由纳米钌颗粒组成的催化体系在铜 N-杂环卡宾改性二氧化硅上一锅法合成烯丙基和烷基胺多组分

  摘要：

  使用单一催化剂材料实现了从胺、甲醛和末端炔烃中一锅法合成有价值的烯丙胺和烷基胺。这种多功能催化系统由二氧化硅载体组成，在其上共同组装了钌纳米粒子和共价功能化的铜N-杂环卡宾 (NHC) 配合物，引入了新一代固定在分子修饰表面上的纳米粒子。通过多种技术研究了所得 Ru@SiO 2 -[Cu-NHC] 材料的结构、结构、形态和电子特性，包括 N 2吸附、固态核磁共振、电子显微镜和 X 射线光电子能谱. Ru@SiO 2-[Cu-NHC] 被发现对一系列烯丙胺和烷基胺的一锅法合成具有活性和选择性，这些产品在精细化工和制药工业中非常重要。详细研究表明，固定化分子 Cu(I)–NHC 络合物负责胺、甲醛和末端炔烃的原子高效 A 3偶联，而所得炔丙基胺的选择性氢化由 Ru(0) 纳米粒子催化. 在单个载体上结合分子和纳米粒子位点的设计策略和制备方法非常灵活，为开发能够在一锅中进行复杂反应序列的多功能催化系统开辟了道路。

  DOI：

  10.1021/acscatal.2c04044

文献信息

• Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning
  申请人：Johnson Alan T.

  公开号：US20100286125A1

  公开（公告）日：2010-11-11

  Compounds having the formula wherein the symbols have the meaning described in the specification are hydroxamic acid derivatives of 4-phenyl-4-hydroxy-butyric acid and capable of inhibiting the lethal effects of infection by anthrax bacteria and are useful in the treatment of poisoning by anthrax.

  具有以下式的化合物是4-苯基-4-羟基丁酸的羟肟酸衍生物，能够抑制炭疽细菌感染的致命效应，并且在炭疽中毒的治疗中有用。
• Synthesis and evaluation of novel alkylpiperazines as potential dopamine antagonists
  作者：Richard A. Glennon、John J. Salley、Odd S. Steinsland、Sharon Nelson

  DOI：10.1021/jm00138a007

  日期：1981.6

  Several alkylpiperazines, monocyclic subfragments of known tricyclic neuroleptic agents, were evaluated as dopamine antagonists in the isolated rabbit ear artery preparation. Compound prepared and evaluated are of the general structure Ar-X-(CH2)n-Y, where X = C, O, and N, n = 1-3, and Y, for the most part, was 4-methylpiperazine. Those compounds where X - NH, n = 3, and X = (Z)-CH - CH, n = 2, with

  在分离的兔耳动脉制剂中，几种烷基哌嗪（已知的三环抗精神病药的单环亚片段）被评估为多巴胺拮抗剂。制备和评估的化合物具有一般结构Ar-X-（CH2）nY，其中X = C，O和N，n = 1-3，Y大部分是4-甲基哌嗪。X-NH，n = 3，X =（Z）-CH-CH，n = 2，侧链上有一个吸电子基团的那些化合物，其多巴胺拮抗剂活性与氯氮平相当。结论是，在本研究中使用的受体制剂中，作为多巴胺拮抗剂的最佳活性，吩噻嗪样药物的整个三环结构（或至少大于一个单环系统）是必需的。
• Cinnamide Compound
  申请人：Kimura Teiji

  公开号：US20080070902A1

  公开（公告）日：2008-03-20

  The present invention relates to a compound represented by Formula (I): (wherein Ar 1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar 2 represents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; X 1 represents (1) —C≡C— or (2) a double bond etc. which may be substituted; R 1 and R 2 represent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted) or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents.

  本发明涉及一种由公式(I)表示的化合物：（其中Ar1代表一个咪唑基，可以用1到3个取代基取代；Ar2代表一个吡啶基，嘧啶基或苯基，可以用1到3个取代基取代；X1代表（1）-C≡C-或（2）一个双键等，可以用取代基取代；R1和R2代表例如C1-6烷基或C3-8环烷基，可以用取代基取代）或其药学上可接受的盐，并用作制药剂。
• Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands
  申请人：Hendrix James A.

  公开号：US20090247509A1

  公开（公告）日：2009-10-01

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，其表现出对多巴胺D3受体的选择性结合。另一方面，本发明涉及一种治疗与多巴胺D3受体活性相关的中枢神经系统疾病的方法，该方法包括向需要此类治疗的患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神疾病、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞引起的迟发性运动障碍、吉尔斯-德-拉-图雷综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备所述化合物的方法以及将所述化合物作为多巴胺D3受体成像剂的制备和使用方法。
• Lck inhibitors
  申请人：Buehlmayer Peter

  公开号：US20100029636A1

  公开（公告）日：2010-02-04

  The invention relates to novel pyrazolo[1,5-A]pyrimidine compounds of Formula I in which all the variables are as defined in the specification; to their preparation and to their use as Lck kinase inhibitors.

  本发明涉及一种新型的吡唑并[1,5-A]嘧啶化合物，其化学式为I，其中所有变量均如规范中定义的那样；它们的制备和作为Lck激酶抑制剂的用途。